mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation.

advanced therapies corneal epithelium corneal inflammation gene augmentation interleukin-10 messenger RNA polyvinyl alcohol solid lipid nanoparticles topical administration transfection

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
15 Sep 2021
Historique:
received: 26 07 2021
revised: 27 08 2021
accepted: 11 09 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

The anti-inflammatory cytokine Interleukin-10 (IL-10) is considered an efficient treatment for corneal inflammation, in spite of its short half-life and poor eye bioavailability. In the present work, mRNA-based nanomedicinal products based on solid lipid nanoparticles (SLNs) were developed in order to produce IL-10 to treat corneal inflammation. mRNA encoding green fluorescent protein (GFP) or human IL-10 was complexed with different SLNs and ligands. After, physicochemical characterization, transfection efficacy, intracellular disposition, cellular uptake and IL-10 expression of the nanosystems were evaluated

Identifiants

pubmed: 34575548
pii: pharmaceutics13091472
doi: 10.3390/pharmaceutics13091472
pmc: PMC8466377
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Euskal Herriko Unibertsitatea
ID : GIU 20/048

Références

Exp Eye Res. 2018 Nov;176:130-140
pubmed: 29981344
Pharmaceutics. 2020 Apr 07;12(4):
pubmed: 32272615
Molecules. 2021 Jun 09;26(12):
pubmed: 34207756
Eur Cell Mater. 2016 May 24;31:312-22
pubmed: 27215739
Colloids Surf B Biointerfaces. 2014 Feb 1;114:111-20
pubmed: 24176890
Biotechnol Prog. 2008 Jan-Feb;24(1):250-61
pubmed: 18069847
Cell Oncol (Dordr). 2019 Oct;42(5):691-703
pubmed: 31201646
J Control Release. 2015 Nov 10;217:273-83
pubmed: 26400864
Ocul Immunol Inflamm. 2012 Dec;20(6):406-18
pubmed: 23163602
Mater Sci Eng C Mater Biol Appl. 2017 Aug 1;77:895-903
pubmed: 28532107
J Biomed Sci. 2015 May 14;22:31
pubmed: 25971314
Nanomaterials (Basel). 2020 Feb 20;10(2):
pubmed: 32093140
Nanomedicine (Lond). 2018 Aug 1;13(15):1847-1854
pubmed: 29792369
Front Immunol. 2021 Jul 07;12:679344
pubmed: 34305909
Curr Opin Virol. 2021 Jun;48:65-72
pubmed: 33906124
Front Physiol. 2021 Jan 12;11:571416
pubmed: 33510644
Pharmaceutics. 2020 Jun 23;12(6):
pubmed: 32586018
Nat Med. 2021 Jun;27(6):930-932
pubmed: 34059823
Pharmaceutics. 2019 Jul 24;11(8):
pubmed: 31344836
Pharmaceutics. 2021 May 20;13(5):
pubmed: 34065558
Int J Nanomedicine. 2019 Feb 18;14:1213-1227
pubmed: 30863055
Hum Gene Ther. 2019 Aug;30(8):923-945
pubmed: 31020856
Int J Pharm. 2012 Apr 4;425(1-2):35-43
pubmed: 22226874
Adv Drug Deliv Rev. 2002 Nov 1;54 Suppl 1:S131-55
pubmed: 12460720
Adv Biochem Eng Biotechnol. 2020;171:321-368
pubmed: 31492963
Stem Cells Transl Med. 2021 Jan;10(1):39-49
pubmed: 32896982
Materials (Basel). 2021 Mar 11;14(6):
pubmed: 33799585
J Funct Biomater. 2015 Jun 08;6(2):379-94
pubmed: 26062170
Front Bioeng Biotechnol. 2021 Mar 18;9:628137
pubmed: 33816449
Nanomedicine (Lond). 2019 Feb;14(4):465-491
pubmed: 30694726
Eur J Pharm Biopharm. 2016 Dec;109:184-193
pubmed: 27789356
Pharmaceutics. 2020 Dec 18;12(12):
pubmed: 33353013
Adv Drug Deliv Rev. 2007 Jul 10;59(6):444-53
pubmed: 17582648
Cancer Res. 2000 Nov 1;60(21):6045-51
pubmed: 11085526
Genes (Basel). 2019 Apr 09;10(4):
pubmed: 30970664
FEMS Microbiol Lett. 2003 Jan 21;218(1):149-54
pubmed: 12583911
Br J Ophthalmol. 2021 Dec;105(12):1617-1622
pubmed: 33127826
J Clin Diagn Res. 2015 Jan;9(1):GE01-6
pubmed: 25738007
Molecules. 2020 Dec 18;25(24):
pubmed: 33352904
Macromol Biosci. 2021 Jul;21(7):e2100043
pubmed: 34015173
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):279-93
pubmed: 25725262
Expert Opin Drug Deliv. 2016 Dec;13(12):1743-1757
pubmed: 27291069
Arch Ophthalmol. 1981 Feb;99(2):301
pubmed: 7469869
Eur J Pharm Biopharm. 2011 Nov;79(3):495-502
pubmed: 21726641
Int J Pharm. 2014 Apr 25;465(1-2):413-26
pubmed: 24576595
Methods Mol Biol. 2014;1163:183-91
pubmed: 24841307
Pharmaceutics. 2020 Apr 17;12(4):
pubmed: 32316537
Nanomaterials (Basel). 2021 Jun 07;11(6):
pubmed: 34200384
Optometry. 2004 Mar;75(3):161-8
pubmed: 15058697
Pharmaceutics. 2018 Feb 27;10(1):
pubmed: 29495528
Eur J Pharm Sci. 2021 Nov 1;166:105906
pubmed: 34118409
J Control Release. 2015 Jul 10;209:77-87
pubmed: 25912408
Pharmaceutics. 2019 Dec 24;12(1):
pubmed: 31878298
Biomater Sci. 2018 Jan 30;6(2):398-406
pubmed: 29337327

Auteurs

Itziar Gómez-Aguado (I)

Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de Investigación Lascaray Ikergunea, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
Bioaraba, Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, 01006 Vitoria-Gasteiz, Spain.

Julen Rodríguez-Castejón (J)

Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de Investigación Lascaray Ikergunea, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
Bioaraba, Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, 01006 Vitoria-Gasteiz, Spain.

Marina Beraza-Millor (M)

Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de Investigación Lascaray Ikergunea, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
Bioaraba, Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, 01006 Vitoria-Gasteiz, Spain.

Mónica Vicente-Pascual (M)

Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de Investigación Lascaray Ikergunea, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.

Alicia Rodríguez-Gascón (A)

Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de Investigación Lascaray Ikergunea, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
Bioaraba, Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, 01006 Vitoria-Gasteiz, Spain.

Sara Garelli (S)

Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via Pietro Giuria 9, 10125 Torino, Italy.

Luigi Battaglia (L)

Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via Pietro Giuria 9, 10125 Torino, Italy.

Ana Del Pozo-Rodríguez (A)

Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de Investigación Lascaray Ikergunea, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
Bioaraba, Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, 01006 Vitoria-Gasteiz, Spain.

María Ángeles Solinís (MÁ)

Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de Investigación Lascaray Ikergunea, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
Bioaraba, Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, 01006 Vitoria-Gasteiz, Spain.

Classifications MeSH